Tumour immunology: Alternative perspectives

Scandinavian Journal of Immunology

Volumn 46, Issue 5, 1997, Pages 437-444

  Seljelid, R ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN RECOGNITION; B LYMPHOCYTE ACTIVATION; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 0030669875     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-160.x     Document Type: Review

References (67)

1. Burnet M. Immunological Surveillance. Oxford: Pergamon Press, 1970.
2. van Ravenswaay-Claasen HH, Klein PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD 16 macrophages in antitumor cytoxicity. Lab Invest 1992;67:166-74.
3. Ostenstad B, Sioud M, Lea T, Schlichting E, Harboe M. Limited heterogeneity in the T cell receptor V-gene usage in lymphocytes infiltrating human colorectal tumours. Brit J Cancer 1994;69:1078-82.
4. Hilders CG, Houbiers JG, van Ravenswaay-Claasen HH, Veldhuizen RW, Fleuren GJ. Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest 1993;69:651-9.
5. Hilders GC, Ras L, van Eendenburg, Boogen Y, Fleuren GJ. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 1994;57:805-13.
6. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994;180:1-4.
7. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274: 1363-6.
8. Schreiber H. Tumor immunology. In: Paul WE, ed. Fundamental Immunology. New York:Raven Press, 1989, 923-55.
9. Foley E. Antigen properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 1953;13:835-42.
10. Klein G, Sjogren HD, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochtonous host. Cancer Res 1960;20:156-72.
11. North RJ. The murine antitumor immune response and its therapeutic manipulation. Adv Immunol 1984;35:89-114.
12. Kagi D, Ledermann B, Burki K et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficie mice. Nature 1994;369:31-7.
13. Burrows SR, Fernan A, Argaet V, Suhrbier A. Bystander apoptosis induced by CD8 cytotoxic T cell (CTL) clones; implications for CTL lytic mechanisms. Int Immunol 1993;5:1049-58.
14. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
15. Seljelid R. A water-soluble aminated β1-3D-glucan derivative causes regression of solid tumors in mice. Bioscience Reports 1986;6:845-51.
16. Seljelid R, Figenschau Y, Bøgwald J, Rasmussen L-T, Austgulen R. Evidence that tumor necrosis induced by aminated β1-3D polyglucose is mediated by a concerted action of local and systemic cytokines. Scand J Immunol 1989;30:687-94.
17. Sveinbjørnsson B, Olsen R, Seternes OM, Seljelid R. Macrophage cytotoxicity against murine Meth A sarcoma involves nitric oxide-mediated apoptosis. Biochem Biophys Res Comm 1996;223:643-9.
18. Metchnikoff E. Comparative Pathology of Inflammation. New York:Dover Publications Inc., 1968.
19. Plytycz B, Seljelid R. Bacterial clearance by the sea urchin. Strongylocentrotus droebachiensis. Develop and Comp Immunol 1993;17:283-9.
20. Prehn RT. Immunostimulation of the lymphodependent phase of neoplastic growth. J Natl Cancer Inst 1977;59:1043-9.
21. Evans R. Macrophages in syngeneic animal tumors. Transplantation 1972;14:468-73.
22. Munthe-Kaas AC, Berg T, Seglen PO, Seljelid R. Mass isolation and culture of rat Kupffer cells. J Exp Med 1975;141:1-10.
23. Bottazzi B, Polentarutti N, Acero R et al. Regulation of macrophage content of neoplasms by chemoattractants. Science 1983;220:210-2.
24. Benomar A, Wang JM, Taraboletti G et al. Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. J Immunol 1987;138:2372-9.
25. Cianciolo G, Hunter J, Silva J, Haskill JS, Snyderman R. Inhibitors of monocyle responses to chemotaxins are present in human cancerous effusion and react with monoclonal antibodies to the P15 (E) structural protein of retroviruses. Clin Invest 1981;68:831-44.
26. Peri G, Rossi V, Taraboletti G, Erroi A, Mantovani A. Ia antigen expression and 1L-1 activity in murine tumour-associated macrophages. Immunol 1986;59:527-33.
27. Polverini PJ, Leibovic SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984;51:635-42.
28. Varesio L, Herberman RB, Gerson JM, Holden HT. Suppression of lymphokine production by macrophages infiltrating murine virus-induced tumors. Int J Cancer 1979;24:97-102.
29. Dvorak HF. Tumors: wounds that do not heal. New Engl J Med 1986;315:1650-9.
30. Nagy JA, Brown LF, Senger DR. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989;948:305-26.
31. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1986;313:745-7.
32. Lindmark G, Sundberg C, Glimelius B et al. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 1993;69:682-9.
33. Korc-Grodizicki B, Ren N, Hilf R. Insulin-like growth factor-binding proteins in R3230 AC mammary tumors of intact and diabetic rats. Endocrinology 1993;133:2362-70.
34. Iozzo RV, Cohen I. Altered proteoglycan gene expression and tumor stroma. Experientia 1994;70:199-214.
35. Yeo T-K, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common to healing wounds and tumors. Am J Pathol 1991;138:1437-50.
36. Pyke C, Kristensen P, Blasi F et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-67.
37. Schmitt M, Kanayama N, Janicke F et al. Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro uPA) by granulocyte elastase prevents subsequent activation by plasmin. Adv Exp Med Biol 1991;297:111-28.
38. Weismann G, Dukor P, Zurier RB. Effect of cyclic AMP on release of lysosomal enzymes from phagocytes. Nature New Biol 1971;231:131-5.
39. Wahl LM, Wahl SM, Mergenhagen SE, Martin GR. Collagenase production by endotoxin-activated macrophages. Proc Natl Acad Sci 1974;71:3598-601.
40. Werb Z, Gordon S. Elastase secretion by stimulated macrophages. J Exp Med 1975;142:361-77.
41. Unkeless JC, Gordon S, Reich E. Secretion of plasminogen activator by stimulated macrophages. J Exp Med 1974;139:834-50.
42. Johansson S, Rubin K, Hook M, Ahlgren T, Seljelid R. In vitro biosynthesis of cold insoluble globulin (fibronectin) by mouse peritoneal macrophages. FEBS Letters 1979;105:313-6.
43. Kolset SO, Kjellen L, Seljelid R, Lindahl U. Changes in glycosaminoglycan biosynthesis during differentiation in vitro of human monocytes. Biochem J 1983;210:661-7.
44. Rivers RPA, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Hematol 1975;30:311-6.
45. Østerud B, Lindahl U, Seljelid R. Macrophages produce blood coagulation factors. FEBS Letters 1980;120:41-3.
46. Lindahl U, Pejler G, Bøgwald J, Seljelid R. A prothrombinase complex of mouse peritoneal macrophages. Arch Biochem and Biophys 1989;2731:180-8.
47. Pejler G, Seljelid R. Inactivation of thrombin by murine peritoneal macrophages. J Biol Chem 1992;267:3136-42.
48. Carney DH, Cunningham DD. Role of specific cell surface receptors in thrombin-stimulated cell division. Cell 1978;15:1341-9.
49. Bar-Shavit R, Kahn A, Fenton JW II, Wilner GD. Chemotactic response of monocytes to thrombin. J Cell Biol 1983;96:282-5.
50. Razin E, Baranes D, Marx G. Thrombin-mast cell interactions. Exp Cell Res 1985;160:380-6.
51. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP 140. J Biol Chem 1989;264:7768-71.
52. Leibovic SJ, Ross R. A macrophage-dependent factor that stimulates the proliferation of fibroblasts in vitro. Am J Pathol 1976;84:501-13.
53. Metcalf D. The molecular control of normal and leukemic granulocytes and macrophages. Proc Roy Soc (Biol.) 1987;230:389-423.
54. Hamburger AW, While CP. Growth factors for human tumor clonogenic cells elaborated by macrophages isolated from human malignant effusion. Cancer Immunol Immunother 1986;22:186-90.
55. Gery I, Gershon K, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. J Exp Med 1972;136:128-42.
56. Auger MJ, Ross JA. The biology of the macrophage. In: Lewis CE, McGee J.O'D, eds. The Macrophage. Oxford:Oxford University Press, 1992:2-74.
57. Old LJ, Boyse EA. Current enigmas in cancer research. In: Harvey Lectures Series 67. New York: Academic Press, 1973;273-315.
58. Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988;9:28-31.
59. Vilcek J, Palombella VJ, Henriksen-DeStefano D et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship. J Exp Med 1986;163:632-41.
60. Yamasu K, Onoe H, Soma GI, Oshima H, Mizuno D. Secretion of tumor necrosis factor during fetal and neonatal development of the mouse: ontogenic inflammation. J Biol Response Modif 1989;8:644-55.
61. Olstad R, Degre M, Seljelid R. Production of immune interferon (type II) in cocultures of mouse peritoneal macrophages and syngeneic tumor cells. Scand J Immunol 1981;13:605-8.
62. Plytycz T, Pedersen A, Bogworld J, Seljelid R. In vitro interactions of murine peritoneal macrophages and sarcoma cells. I. Virchows Arch 1986;50:285-92.
63. Plytycz T, Espelid S, Gaupliaa T. In vitro interactions of murine peritoneal macrophages and sarcoma cells. II. Virchows Arch 1986;50:293-7.
64. Olstad R, Gaudernack G, Kaplan G, Seljelid R, T- and B-cell-independent activation of syngeneic macrophages by murine sarcoma cells. Cancer Res 1980;40:2054-60.
65. Munzarova M, Kovarik J. Is cancer a macrophage-mediated autoaggressive disease? Lancet 1987:ai952-4.
66. Donehower LA, Bradley A. The tumor suppressor p.53. Biochem Biophys Acta 1993;1155:181-205.
67. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.